ArticleAntimicrobial agents and chemotherapy2018
Comparison of
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Acquired linezolid resistance in DR-TB: genotype-phenotype discordance and molecular heterogeneity in a retrospective cohort.BMC infectious diseases · 2026Article
- Characteristic exploration of Mycobacterium tuberculosis isolated from patients with linezolid-treated multidrug-resistant tuberculosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- A Frameshift Mutation in the MethyltransferaseComputational and structural biotechnology journal · 2026Article
- Drug resistance of Mycobacterium tuberculosis to linezolid and delamanid: a case report from Bukavu, Democratic Republic of Congo.BMC infectious diseases · 2025Article
- Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon.Acta pharmaceutica Sinica. B · 2025Review
- Comparative In Vitro Drug Susceptibility Study of Five Oxazolidinones AgainstPathogens (Basel, Switzerland) · 2025Article
- Country-level heterogeneity in MDR-TB drug susceptibility supports country-specific policy development.Frontiers in tuberculosis · 2025Article
- ThePeerJ · 2025Review
- Comparative pharmacokinetics study of two tablet formulations of delpazolid, a novel oxazolidinone class antibiotic.Translational and clinical pharmacology · 2024Article
- Widespread loss-of-function mutations implicating preexisting resistance to new or repurposed anti-tuberculosis drugs.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2024Article
- Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen.Nature communications · 2024Article
- New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?Pharmaceutics · 2024Review
- Identification ofInfection and drug resistance · 2024Review
- Effectiveness and safety of regimens containing linezolid for treatment of Mycobacterium abscessus pulmonary Disease.Annals of clinical microbiology and antimicrobials · 2023Article
- Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection.Scientific reports · 2023Article
- Staph wars: the antibiotic pipeline strikes back.Microbiology (Reading, England) · 2023Review
- Antibiotics in the clinical pipeline as of December 2022.The Journal of antibiotics · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxazolidinones are efficacious in treating mycobacterial infections, including tuberculosis (TB) caused by drug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.